Cyclooxygenase-2-specific inhibitors and cardiorenal function: A randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients

American Journal of Therapeutics

Volumn 8, Issue 2, 2001, Pages 85-95

  Whelton, Andrew ^a   Fort, John G ^b   Puma, Joseph A ^c   Normandin, Diane ^d   Bello, Alfonso E ^b   Verburg, Kenneth M ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d Clinical Research of West Florida Tampa   (United States)

Author keywords

Cardiovascular risk; Celecoxib; Cyclooxygenase 2 specific inhibitors; Edema; Isolated systolic hypertension; NSAID; Osteoarthritis; Rofecoxib

Indexed keywords

ANTIHYPERTENSIVE AGENT; CELECOXIB; LACTONE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE; ROFECOXIB; SULFONAMIDE; SULFONE;

AGED; ARTICLE; BIOSYNTHESIS; CARDIOVASCULAR SYSTEM; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG INTERACTION; EDEMA; FEMALE; HUMAN; HYPERTENSION; KIDNEY; MALE; MULTICENTER STUDY; OSTEOARTHRITIS; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR SYSTEM; CYCLOOXYGENASE INHIBITORS; DRUG INTERACTIONS; EDEMA; FEMALE; HUMANS; HYPERTENSION; KIDNEY; LACTONES; MALE; OSTEOARTHRITIS; PROSTAGLANDINS; PYRAZOLES; SULFONAMIDES; SULFONES;

EID: 0035286901     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-200103000-00003     Document Type: Article

References (35)

1. Desai MM, Zhang P, Hennessy CH: Surveillance for morbidity and mortality among older adults-United States, 1995-1996. MMWR CDC Surveill Summ 1999;48:7-25.
2. Lawrence RC, Helmick CG, Arnett FC, et al: Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41: 778-799.
3. Black HR: Isolated systolic hypertension in the elderly: lessons from clinical trials and future directions. J Hypertens 1999;17(Suppl 5):S49-S54.
4. Izzo JL Jr., Levy D, Black HR: Clinical advisory statement. Importance of systolic blood pressure in older Americans. Hypertension 2000;35:1021-1024.
5. Houston MC: Nonsteroidal anti-inflammatory drugs and antihypertensives. Am J Med 1991;90:42S-47S.
6. Pope JE, Andersen JJ, Felson DT: A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993;153:477-484.
7. Brater DC: Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2 selective inhibition. Am J Med 1999;107:65S-70S.
8. Johnson AG, Nguyen TV, Day RO: Do nonsteroidal anti-inflammatory drugs affect blood pressure? A metaanalysis. Ann Intern Med 1994;121:289-300.
9. de Leeuw PW: Nonsteroidal anti-inflammatory drugs and hypertension. The risks in perspective. Drugs 1996; 51:179-187.
10. Whelton A, Maurath CJ, Verburg KM, et al: Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther 2000,7:159-176.
11. Whelton A: Nephrotoxicity of nonsteroidal antiinflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999;106:13S-24S.
12. Goldstein JL, Silverstein FE, Agrawal NM, et al: Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000;95:1681-1690.
13. Leese PT, Hubbard RC, Karim A, et al: Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 2000;40:124-132.
14. Langman MJ, Jensen DM, Watson DJ, et al: Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-1933.
15. Cryer B, Gottesdiener K, Gertz B, et al: In vivo effects of rofecoxib, a new cyclooxygenase (COX)-2 inhibitor, on gastric mucosal prostaglandin (PG) and serum thromboxane B2 (TXB2) synthesis in healthy humans [abstract]. Gastroenterology 1999;116:G0611.
16. Silverstein FE, Faich G, Goldstein JL, et al: Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-1255.
17. Bombardier C, Laine L, Reicin A, et al: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-1528.
18. Whelton A: Aspects of treatment with conventional NSAIDs versus COX-2-specific inhibitors. Am J Med 2001, in press.
19. Swan SK, Rudy DW, Lasseter KC, et al: Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med 2000;133:1-9.
20. Whelton A, Schulman G, Wallemark C, et al: Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000;160:1465-1470.
21. Vioxx® [package insert]. Whitehouse Station, NJ: Merck & Co., Inc., March 2000.
22. Celebrex® [package insert]. Skokie, IL: Searle & Co., Inc., December 1999.
23. Physician Drug & Diagnosis Audit (PDDA), Scott-Levin, Inc., 2000.
24. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-3264.
25. Staessen JA, Fagard R, Thijs L, et al: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-764.
26. Catella-Lawson F, McAdam B, Morrison BW, et al: Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999;289:735-741.
27. Epstein M: Aging and the kidney. J Am Soc Nephrol 1996;7:1106-1122.
28. Page J, Henry D: Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med 2000;160:777-784.
29. Heerdink ER, Leufkens HG, Herings RM, et al: NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med 1998;158:1108-1112.
30. ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000;283:1967-1975.
31. Collins R, Peto R, MacMahon S, et al: Blood pressure, stroke, and coronary heart disease. Part 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335:827-838.
32. Hypertension Detection and Follow-up Program Cooperative Group: Effect of stepped care treatment on the incidence of myocardial infarction and angina pectoris: 5-year findings of the Hypertension Detection and Follow-Up Program. Hypertension 1984;6:I198-I206.
33. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-2446.
34. 1999 World Health Organization International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999;17: 151-183.
35. Staessen JA, Gasowski J, Wang JG, et al: Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000;355: 865-872.